Moderna [MRNA] vs Vertex [VRTX] Detailed Stock Comparison
Moderna
NASDAQ
Loading...
Vertex
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Moderna wins in 7 metrics, Vertex wins in 11 metrics, with 0 ties. Vertex appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Moderna | Vertex | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 24.97 | 27.47 | Moderna |
| Price-to-Book Ratio | 1.05 | 5.90 | Moderna |
| Debt-to-Equity Ratio | 7.88 | 8.89 | Moderna |
| PEG Ratio | -0.69 | -0.21 | Moderna |
| EV/EBITDA | -1.78 | 20.10 | Moderna |
| Profit Margin (TTM) | -94.31% | 31.86% | Vertex |
| Operating Margin (TTM) | -638.73% | 38.93% | Vertex |
| EBITDA Margin (TTM) | N/A | 38.93% | N/A |
| Return on Equity | -27.50% | 22.77% | Vertex |
| Return on Assets (TTM) | -14.77% | 13.09% | Vertex |
| Free Cash Flow (TTM) | $-4.06B | $-978.00M | Vertex |
| 1-Year Return | -52.87% | -10.20% | Vertex |
| Price-to-Sales Ratio (TTM) | 3.20 | 8.88 | Moderna |
| Enterprise Value | $5.47B | $96.50B | Vertex |
| EV/Revenue Ratio | 1.78 | 8.45 | Moderna |
| Gross Profit Margin (TTM) | 13.14% | 86.25% | Vertex |
| Revenue per Share (TTM) | $8 | $44 | Vertex |
| Earnings per Share (Diluted) | $-7.77 | $14.39 | Vertex |
| Beta (Stock Volatility) | 1.93 | 0.44 | Vertex |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Moderna vs Vertex Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Moderna | 2.79% | 15.28% | 17.28% | -6.31% | 2.34% | -32.45% |
| Vertex | 1.15% | 7.07% | 1.96% | -10.54% | -15.44% | 0.76% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Moderna | -52.87% | -76.22% | -61.14% | 52.53% | 52.53% | 52.53% |
| Vertex | -10.20% | 38.49% | 51.45% | 271.68% | 1,057.89% | 1,798.98% |
News Based Sentiment: Moderna vs Vertex
Moderna
News based Sentiment: MIXED
September presented a mixed bag for Moderna, with encouraging developments in its oncology pipeline and manufacturing capacity offset by lowered financial guidance, a declining stock price, and mixed institutional investor activity. The company is actively working to diversify beyond COVID-19, but faces significant challenges in the near term.
Vertex
News based Sentiment: POSITIVE
Vertex Pharmaceuticals delivered strong financial results in Q2 2025 and raised its full-year guidance, coupled with positive developments in its pipeline and favorable analyst coverage. This combination of factors indicates a positive trajectory for the company and strengthens the investment case.
Performance & Financial Health Analysis: Moderna vs Vertex
| Metric | MRNA | VRTX |
|---|---|---|
| Market Information | ||
| Market Cap | $9.86B | $100.41B |
| Market Cap Category | Mid cap | Large cap |
| 10 Day Avg. Volume | 11,903,250 | 2,025,380 |
| 90 Day Avg. Volume | 11,598,347 | 1,632,117 |
| Last Close | $28.37 | $408.85 |
| 52 Week Range | $23.15 - $63.69 | $362.50 - $519.88 |
| % from 52W High | -55.46% | -21.36% |
| All-Time High | $497.49 (Aug 09, 2021) | $519.88 (Nov 04, 2024) |
| % from All-Time High | -94.30% | -21.36% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.41% | 0.12% |
| Quarterly Earnings Growth | -0.38% | 0.12% |
| Financial Health | ||
| Profit Margin (TTM) | -0.94% | 0.32% |
| Operating Margin (TTM) | -6.39% | 0.39% |
| Return on Equity (TTM) | -0.28% | 0.23% |
| Debt to Equity (MRQ) | 7.88 | 8.89 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $24.16 | $67.02 |
| Cash per Share (MRQ) | $13.19 | $24.90 |
| Operating Cash Flow (TTM) | $-2,696,999,936 | $3.85B |
| Levered Free Cash Flow (TTM) | $-2,864,375,040 | $2.91B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Moderna vs Vertex
| Metric | MRNA | VRTX |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 24.97 | 27.47 |
| Forward P/E | -2.91 | 21.06 |
| PEG Ratio | -0.69 | -0.21 |
| Price to Sales (TTM) | 3.20 | 8.88 |
| Price to Book (MRQ) | 1.05 | 5.90 |
| Market Capitalization | ||
| Market Capitalization | $9.86B | $100.41B |
| Enterprise Value | $5.47B | $96.50B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.78 | 8.45 |
| Enterprise to EBITDA | -1.78 | 20.10 |
| Risk & Other Metrics | ||
| Beta | 1.93 | 0.44 |
| Book Value per Share (MRQ) | $24.16 | $67.02 |
Financial Statements Comparison: Moderna vs Vertex
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | MRNA | VRTX |
|---|---|---|
| Revenue/Sales | $107.00M | $2.96B |
| Cost of Goods Sold | $90.00M | $407.50M |
| Gross Profit | $17.00M | $2.56B |
| Research & Development | $856.00M | $978.40M |
| Operating Income (EBIT) | $-1.05B | $1.15B |
| EBITDA | $-917.00M | $1.34B |
| Pre-Tax Income | $-964.00M | $1.28B |
| Income Tax | $7.00M | $250.10M |
| Net Income (Profit) | $-971.00M | $1.03B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | MRNA | VRTX |
|---|---|---|
| Cash & Equivalents | $1.62B | $4.67B |
| Total Current Assets | $6.77B | $10.01B |
| Total Current Liabilities | $1.60B | $3.78B |
| Long-Term Debt | $702.00M | $1.65B |
| Total Shareholders Equity | $10.07B | $16.50B |
| Retained Earnings | $9.07B | $10.25B |
| Property, Plant & Equipment | $1.25B | $2.63B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | MRNA | VRTX |
|---|---|---|
| Operating Cash Flow | $-691.00M | $404.90M |
| Capital Expenditures | $-117.00M | $-40.70M |
| Free Cash Flow | $-1.16B | $778.20M |
| Debt Repayment | N/A | $-1.30M |
| Common Stock Repurchase | N/A | $-696.60M |
Short Interest & Institutional Ownership Analysis
| Metric | MRNA | VRTX |
|---|---|---|
| Shares Short | 63.31M | 4.05M |
| Short Ratio | 5.58 | 2.83 |
| Short % of Float | 0.23% | 0.02% |
| Average Daily Volume (10 Day) | 11,903,250 | 2,025,380 |
| Average Daily Volume (90 Day) | 11,598,347 | 1,632,117 |
| Shares Outstanding | 386.00M | 256.94M |
| Float Shares | 363.29M | 255.58M |
| % Held by Insiders | 0.07% | 0.00% |
| % Held by Institutions | 0.75% | 0.98% |
Dividend Analysis & Yield Comparison: Moderna vs Vertex
| Metric | MRNA | VRTX |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |